FIELD: biotechnology.
SUBSTANCE: invention relates to a system containing the following: nRNA containing a targeting domain complementary to the target sequence from the transforming growth factor receptor II geneβ (TGFBR2), and RNA-directed nuclease, as well as to the cell containing it.
EFFECT: invention is effective for mediated TGF-β inhibition of T cells in the context of tumor therapy.
21 cl, 24 dwg, 9 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF PRODUCING CELLS EXPRESSING RECOMBINANT RECEPTOR AND RELATED COMPOSITIONS | 2019 |
|
RU2835579C2 |
| COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY | 2016 |
|
RU2771624C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| DNA-CONTAINING POLYNUCLEOTIDES AND GUIDE SEQUENCES FOR CRISPR TYPE V SYSTEMS AND METHODS FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2832314C1 |
| GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
| CRISPR ENZYME MUTATIONS REDUCING NON-TARGETED EFFECTS | 2016 |
|
RU2752834C2 |
| METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF HOMING-ENDONUCLEASE PD-1 | 2017 |
|
RU2781083C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF ENDONUCLEASE CBLB | 2018 |
|
RU2779097C2 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
